CTX310 Lipid Disorder: Phase 1 Trial Shows Prom...

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
China Medical Research Challenges: Pushing Boundaries Amid Ethical and Qualit...
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
Social Media Policy Action: Protecting Youth from Cognitive Risks
Colorectal Cancer Markers: Discovering Region-Specific Drivers for Precision ...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine a...
Transforming Cancer Treatment: Implications of Subcutaneous Pembrolizumab App...
NIVOPOSTOP Trial Results: A Landmark Breakthrough in Head and Neck Cancer Tre...
Addressing GLP-1 Access Inequity: Lessons from HIV/AIDS Mobilization
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth